MERCK & CO. INC. (MRK)
Market CLOSE
SOURCE; NYSE
As of May 16, 2012 4:01 pm. Quotes are delayed by at least 15 minutes
|
$38.23 Last Trade |
+0.49 Change |
15,334,413 Volume |
$37.74 Prev. Close |
|
+1.30% Change (%) |
zack's rank
- No Zack's Rank available for this symbol.
market grader
68.5
FOX BUSINESS NEWS ON MRK
- US Judge Upholds Validity Of Merck's Vytorin Patent - Apr 27, 2012
- Stocks Rise as Solid Earnings Trump GDP Data - Apr 27, 2012
- Stocks Jump on Week Amid Solid Corporate Earnings - Apr 27, 2012
- Merck 1Q Net Rises 67% On Lower Costs; Sales Growth Slows - Apr 27, 2012
- Merck Stirs Up 67% Jump in 1Q Profit - Apr 27, 2012
- Stock Futures Climb as Traders Shrug Off GDP Miss - Apr 27, 2012
- Merck Profit Rises - Apr 27, 2012
- EU Body Backs AstraZeneca, Bristol's Diabetes Drug US Rejected - Apr 20, 2012
- Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx - Apr 19, 2012
partner headlines ON MRK
- 2 Reasons That Cystic Fibrosis Trumps Hep C - The Motley Fool
- Johnson & Johnson: Levaquin Success Great For Investors - The Motley Fool
- This Biotech's for Sale! Reportedly. - The Motley Fool
- S&P Bullish On Biotech ETFs (FBT, IBB, XBI) - Benzinga
- Has Ariad Pharmaceuticals Become the Perfect Stock? - The Motley Fool
- The Dow Makes It 8 Drops in 9 Days - The Motley Fool
- 4 Winners As the Dow Gets Pummeled - The Motley Fool
- Investors Seeking Defensive Stocks Where 3% to Over 5% Dividends Rule! - 24/7 Wall St.
- Still in the Chips - Barron's
- The Shorts Report: 10 Mega-Caps With Increased Short Selling - Benzinga
- This Biotech Is No One-Trick Pony - The Motley Fool
- Has XOMA Become the Perfect Stock? - The Motley Fool
- Simcere Misses on all Fronts - Analyst Blog - Zacks
- How High Can Vertex Pharmaceuticals Fly? - The Motley Fool
- Simcere Misses on all Fronts - Analyst Blog - Nasdaq
- Barron's 500 - Barron's
